Get the Stockscreener App
3.53
2.22%
-0.08
Perspective Therapeutics Inc stock is traded at $3.53, with a volume of 1.11M.
It is down -2.22% in the last 24 hours and up +34.22% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.61
Open:
$3.57
24h Volume:
1.11M
Relative Volume:
1.11
Market Cap:
$254.60M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-20.57
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+2.92%
1M Performance:
+34.22%
6M Performance:
+14.98%
1Y Performance:
-65.86%
1-Day Range:
$3.51
$3.77
1-Week Range:
$3.04
$3.77
52-Week Range:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.53 | 254.60M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
Ameriprise Financial Inc. Sells 645,170 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
151,610 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Acquired by Two Sigma Advisers LP - Defense World
ProShare Advisors LLC Acquires 5,011 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Rating Increased to Moderate Buy at Royal Bank of Canada - Defense World
Perspective Therapeutics (CATX) Price Target Raised by RBC Capital | CATX Stock News - GuruFocus
Perspective Therapeutics (CATX) Gets a Buy from Scotiabank - The Globe and Mail
RBC Capital Boosts Price Target for Perspective Therapeutics (CA - GuruFocus
Perspective Therapeutics Updates on Radiopharmaceutical Advancements - TipRanks
RBC Capital raises Perspective Therapeutics stock price target to $16 By Investing.com - Investing.com Nigeria
RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Capital raises Perspective Therapeutics stock price target to $16 - Investing.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Nuveen Asset Management LLC - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Deutsche Bank AG - Defense World
Two Sigma Investments LP Takes $2.08 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus
Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - The Manila Times
Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com
Perspective Therapeutics Announces Voting Results By Investing.com - Investing.com Canada
Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks
Perspective Therapeutics Announces Voting Results - Investing.com
Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN
Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria
Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Cap:
|
Volume (24h):